Total Valuation
Pharming Group has a market cap or net worth of €710.61M. The enterprise value is €1.08K.
Market Cap€710.61M
Enterprise Value€1.08K
Share Statistics
Pharming Group has 70,778,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding70,778,120
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pharming Group’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.05%.
Return on Equity (ROE)0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)1.05%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee924.16K
Profits Per Employee31.57K
Employee Count407
Asset Turnover0.75
Inventory Turnover0.70
Valuation Ratios
The current PE Ratio of Pharming Group is 80.7. Pharming Group’s PEG ratio is -3.60.
PE Ratio80.7
PS Ratio3.35
PB Ratio4.55
Price to Fair Value4.55
Price to FCF23.36
Price to Operating Cash Flow26.88
PEG Ratio-3.60
Income Statement
In the last 12 months, Pharming Group had revenue of 376.13M and earned 2.85M in profits. Earnings per share was 0.04.
Revenue376.13M
Gross Profit330.63M
Operating Income20.88M
Pretax Income12.85M
Net Income2.85M
EBITDA34.78M
Earnings Per Share (EPS)0.04
Cash Flow
In the last 12 months, operating cash flow was 32.00M and capital expenditures -659.45K, giving a free cash flow of 31.34M billion.
Operating Cash Flow32.00M
Free Cash Flow31.34M
Free Cash Flow per Share0.44
Dividends & Yields
Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change3.19%
50-Day Moving Average10.65
200-Day Moving Average12.23
Relative Strength Index (RSI)45.97
Average Volume (3m)0.00
Important Dates
Pharming Group upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Pharming Group as a current ratio of 2.59, with Debt / Equity ratio of 49.31%
Current Ratio2.59
Quick Ratio2.03
Debt to Market Cap0.08
Net Debt to EBITDA-0.87
Interest Coverage Ratio1.95
Taxes
In the past 12 months, Pharming Group has paid 10.31M in taxes.
Income Tax10.31M
Effective Tax Rate0.80
Enterprise Valuation
Pharming Group EV to EBITDA ratio is 35.36, with an EV/FCF ratio of 22.80.
EV to Sales3.27
EV to EBITDA35.36
EV to Free Cash Flow22.80
EV to Operating Cash Flow22.48
Balance Sheet
Pharming Group has €158.28M in cash and marketable securities with €113.30M in debt, giving a net cash position of €44.99M billion.
Cash & Marketable Securities€158.28M
Total Debt€113.30M
Net Cash€44.99M
Net Cash Per Share€0.64
Tangible Book Value Per Share€1.98
Margins
Gross margin is 86.50%, with operating margin of 5.55%, and net profit margin of 0.76%.
Gross Margin86.50%
Operating Margin5.55%
Pretax Margin3.42%
Net Profit Margin0.76%
EBITDA Margin9.25%
EBIT Margin6.27%
Analyst Forecast
The average price target for Pharming Group is €32.54, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€32.54
Price Target Upside201.28% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast0.59%
EPS Growth Forecast―